Wave's pivotal trial, Dr. William Abraham is working on another heart failure trial as the new CMO at Cardiac Dimensions.

In today’s ACT Brief, we explore how real-world data can improve protocol design and feasibility, highlight new findings from ...

Existing frameworks for explainable artificial intelligence (XAI) and AI governance, such as the EU AI Act and the NIST AI ...

The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...

"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...

As the world becomes more digital, clinical research is evolving. One major change is the rise of decentralized clinical ...

NYU Langone’s Center for Multisite Studies is led by experts who are experienced in managing and supporting research.

Agreement on the design of the single confirmatory Phase 3 superiority study required to support the submission of a Marketing Authorization Application (MAA) with the primary efficacy endpoint in ...

Design Therapeutics, Inc. (($DSGN)) announced an update on their ongoing clinical study. Study Overview: Design Therapeutics, Inc. is conducting a ...

PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...